查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2037548

mRNA治療市場預測——全球按治療方法、mRNA構建體、遞送系統、應用、最終用戶、分銷管道和地區分類的分析——2034年

mRNA Therapeutics Market Forecasts to 2034 - Global Analysis By Therapy Type, mRNA Construct Type, Delivery System, Application, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

全球 mRNA 療法市場預計到 2026 年將達到 130 億美元，並在預測期內以 21.1% 的複合年成長率成長，到 2034 年達到 603 億美元。

mRNA療法利用傳訊RNA分子指導細胞產生特定蛋白質，進而預防、治療或治癒疾病。這種創新方法因新冠疫苗而備受全球關注，如今正擴展到腫瘤學、罕見疾病和自體免疫疾病領域。與傳統治療方法不同，mRNA可以快速設計和開發，高效大規模生產，並為個人化醫療提供了一個多功能平台。該市場涵蓋脂質奈米顆粒遞送系統、修飾的mRNA序列以及正在變革製藥行業的先進製造技術。

mRNA新冠疫苗取得前所未有的成功

新冠疫情期間mRNA疫苗的快速研發和全球部署，充分展現了該平台的速度、有效性和擴充性，從而激發了前所未有的投資和監管信心。超過90%的臨床成功率證明，mRNA疫苗在預防重症方面具有顯著優勢，已超越了小眾應用領域，成為一種切實可行的治療方法。這項突破性成就加速了其他mRNA候選藥物的研發進程，製造商正利用現有的生產基礎設施和低溫運輸物流系統進行生產。政府和私人投資者已投入數十億美元用於拓展mRNA技術能力，建構了一條強大的研發管線，目標病毒包括呼吸道融合細胞病毒、流感病毒和巨細胞病毒。這次疫情有效地發揮了大規模真實世界檢驗試驗的作用，使mRNA療法從「前景廣闊的概念」永久躍升為「主流醫療解決方案」。

嚴格的低溫運輸儲存要求

mRNA分子固有的不穩定性使其需要超低溫儲存和專門的運輸基礎設施，這限制了資源匱乏地區的取得途徑。大多數mRNA製劑需要在攝氏-20至-80度之間保存，這需要昂貴的冷凍庫、溫控運輸容器和持續監測系統。缺乏這些基礎設施的醫療機構在應用這些製劑方面面臨著巨大的障礙，造成了已開發國家和開發中國家之間在獲取治療方面的差距。雖然對耐熱製劑的研究正在取得進展，但目前市售產品仍依賴複雜的低溫運輸。這種物流負擔增加了整體治療成本，使緊急部署方案更加複雜，並減緩了新療法在農村和低收入國家的市場滲透，而這些國家往往最需要新的治療方法。

個人化癌症疫苗的研發

基因測序和生物資訊學的進步使得開發針對每位患者獨特腫瘤突變的個人化mRNA癌症疫苗成為可能。如今，利用新抗原識別演算法，可以預測免疫抗原性靶點，從而使製造商能夠在數週內設計、生產和接種患者特異性疫苗。在黑色素瘤、非小細胞肺癌和胰腺癌的臨床試驗中，與查核點抑制劑合併使用時，已顯示出令人鼓舞的免疫反應和存活率的提高。這種個人化方法正在將腫瘤治療從標準化化療轉變為精準免疫療法。隨著生產自動化降低生產成本和前置作業時間，個人化癌症疫苗代表著數十億美元的商機，並有望將mRNA的應用範圍從預防擴展到根治性治療。

專利糾紛及智慧財產權訴訟

與mRNA修飾、脂質奈米顆粒遞送和生產過程相關的基礎智慧財產權，一直是主要參與者之間激烈法律戰的焦點。核心專利糾紛會限制研發公司進入市場，造成授權的不確定性，並增加整個產業的法律成本。法院判決關鍵專利無效或縮小其保護範圍，可能削弱持續創新的獎勵。另一方面，過於寬泛的專利保護則會扼殺競爭，維持高價。隨著市場日趨成熟，解決這些智慧財產權糾紛將決定競爭格局，延緩產品上市，並限制能夠將新型mRNA療法商業化的公司數量。

新冠疫情的影響：

新冠疫情已成為mRNA療法發展的決定性催化劑，將數十年的研發潛力濃縮到短短兩年內。緊急使用授權提供了數百萬接種者的真實世界安全性數據，並為未來的核准建立了法律規範。生產能力大幅提升，全球新建了疫苗生產設施以滿足疫苗需求，基礎設施也已可用於其他mRNA產品的生產。修飾核苷酸和脂質等原料的供應鏈網路也顯著成熟。此外，疫情促進了學術機構、生技公司和政府機構之間前所未有的合作，建立了將繼續推動研發管線發展的夥伴關係。在後疫情時代，mRNA平台不再是實驗性療法，而是現代醫學的基石。

在預測期內，感染疾病領域預計將佔據最大的市場佔有率。

預計感染疾病領域將直接繼承新冠疫苗帶來的成長勢頭，並在預測期內佔據最大的市場佔有率。除SARS-CoV-2外，針對流感、呼吸道融合細胞病毒、人類免疫力缺乏病毒、茲卡病毒和鉅巨細胞病毒的mRNA候選藥物也正在推動臨床開發。採用mRNA技術生產的季節性流感疫苗在生產速度方面具有潛在優勢，並且能夠更接近流感季開始時進行病毒株配對。針對多種呼吸道病原體的聯合疫苗正在研發中，這將簡化疫苗接種程序。除了現有的感染疾病疫苗監管管道外，各國政府的儲備計畫和世界衛生組織的採購預計將確保該領域在整個預測期內保持其主導地位。

在預測期內，「製藥和生物技術公司」板塊預計將呈現最高的複合年成長率。

在預測期內，受積極的產品線擴張和生產規模擴大活動的推動，製藥和生物技術公司預計將呈現最高的成長率。大型製藥企業正大力投資mRNA平台，並透過自主研發和策略收購專業生技公司來建立內部研發能力。這些公司正在利用mRNA的可程式設計，探索除感染疾病以外的多種應用領域，包括腫瘤、罕見遺傳疾病和自體免疫疾病。該領域受益於雄厚的研發預算、現有的商業基礎設施和監管方面的專業知識。隨著核准的mRNA產品從臨床試驗走向商業化，製藥和生技公司正獲得越來越大的價值，使其成為成長最快的終端用戶類別。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這主要得益於政府的大力投入、成熟的生物技術生態系統以及新冠疫苗的早期部署。美國已透過「曲速行動」（Operation Warp Speed）及其後續舉措投入數十億美元，用於建立國內生產能力並支持臨床研究。領先的mRNA公司總部均設在該地區，並維護其智慧財產權組合和生產設施。監管機構已為mRNA產品製定了明確的指導路徑，降低了核准的不確定性。完善的醫療基礎設施滿足低溫運輸要求，進一步促進了疫苗的部署。憑藉創新領先地位、生產規模和有利的報銷政策，北美預計將在整個預測期內保持其市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於政府對本地生產能力的大力投資以及臨床研究基礎設施的擴張。中國正優先發展mRNA技術，國內企業正在開發針對多種適應症的候選藥物，並建造大規模生產設施。日本、韓國和印度也同樣認知到mRNA在應對疫情和慢性病管理方面的戰略重要性，並正在投資建設相關平台。大規模的感染疾病負擔為mRNA疫苗創造了巨大的潛在市場。此外，該地區的契約製造組織（CMO）正在擴大業務，以服務全球製藥公司客戶，並加速技術轉移和人才培養。因此，亞太地區正成為mRNA療法市場成長最快的地區。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球mRNA治療市場：依治療方法分類

  • 預防性mRNA治療藥物
  • 治療性mRNA藥物

第6章：全球mRNA治療市場：以mRNA構建體類型分類

  • 常規非複製型mRNA
  • 自擴增mRNA
  • 環狀mRNA
  • 反式擴增的mRNA

第7章 全球mRNA治療市場：依遞送系統分類

  • 脂質奈米顆粒
  • 基於聚合物的體系
  • 陽離子奈米乳液
  • 病毒載體
  • 其他配送系統

第8章：全球mRNA治療市場：依應用分類

  • 感染疾病
  • 腫瘤學
  • 自體免疫疾病
  • 罕見疾病和遺傳疾病
  • 其他用途

第9章：全球mRNA治療市場：依最終用戶分類

  • 醫院和診所
  • 製藥和生物技術公司
  • 研究和學術機構
  • 受託研究機構

第10章 全球mRNA治療市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 直接採購

第11章 全球mRNA治療市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Moderna Inc.
  • BioNTech SE
  • CureVac NV
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Arcturus Therapeutics Holdings Inc.
  • Translate Bio Inc.
  • eTheRNA immunotherapies NV
  • Gritstone bio Inc.
  • Sangamo Therapeutics Inc.
  • Argos Therapeutics Inc.
  • Ethris GmbH
  • Panacea Biotec Limited
  • Takeda Pharmaceutical Company Limited
Product Code: SMRC35963

According to Stratistics MRC, the Global mRNA Therapeutics Market is accounted for $13.0 billion in 2026 and is expected to reach $60.3 billion by 2034 growing at a CAGR of 21.1% during the forecast period. mRNA therapeutics utilize messenger RNA molecules to instruct cells to produce specific proteins that can prevent, treat, or cure diseases. This revolutionary approach gained global prominence through COVID-19 vaccines and is now expanding into oncology, rare diseases, and autoimmune disorders. Unlike traditional therapies, mRNA can be designed rapidly, scaled efficiently, and offers a versatile platform for personalized medicine. The market encompasses lipid nanoparticle delivery systems, modified mRNA sequences, and advanced manufacturing technologies that are reshaping the pharmaceutical landscape.

Market Dynamics:

Driver:

Unprecedented success of mRNA COVID-19 vaccines

The rapid development and global deployment of mRNA vaccines during the pandemic demonstrated the platform's speed, efficacy, and scalability, catalyzing unprecedented investment and regulatory confidence. Clinical success rates exceeding ninety percent for severe disease prevention validated mRNA technology as a viable therapeutic modality beyond niche applications. This breakthrough accelerated timelines for other mRNA candidates, with manufacturers leveraging established manufacturing infrastructure and cold chain logistics. Governments and private investors have committed billions to expand mRNA capabilities, creating a robust pipeline targeting respiratory syncytial virus, influenza, and cytomegalovirus. The pandemic effectively served as a large-scale real-world validation study, permanently elevating mRNA therapeutics from promising concept to mainstream medical solution.

Restraint:

Strict cold chain storage requirements

The inherent instability of mRNA molecules necessitates ultra-low temperature storage and specialized transportation infrastructure, limiting accessibility in resource-limited regions. Most mRNA formulations require temperatures between minus twenty and minus eighty degrees Celsius, demanding expensive freezers, temperature-controlled shipping containers, and continuous monitoring systems. Healthcare facilities lacking this infrastructure face significant barriers to adoption, creating disparities in access between developed and developing nations. While research into thermostable formulations is progressing, current commercial products remain dependent on complex cold chains. This logistical burden increases overall treatment costs and complicates emergency deployment scenarios, slowing market penetration in rural areas and lower-income countries where new therapies are often most needed.

Opportunity:

Expansion into personalized cancer vaccines

Advances in genomic sequencing and bioinformatics are enabling the development of individualized mRNA cancer vaccines tailored to each patient's unique tumor mutations. Neoantigen identification algorithms can now predict immunogenic targets, allowing manufacturers to design, produce, and administer patient-specific vaccines within weeks. Clinical trials in melanoma, non-small cell lung cancer, and pancreatic cancer have shown promising immune responses and survival benefits when combined with checkpoint inhibitors. This personalized approach transforms oncology from one-size-fits-all chemotherapy to precision immunotherapy. As manufacturing automation reduces production costs and turnaround times, personalized cancer vaccines represent a multi-billion dollar opportunity, potentially extending mRNA applications from prevention into curative treatment paradigms.

Threat:

Patent disputes and intellectual property litigation

The foundational intellectual property surrounding mRNA modification, lipid nanoparticle delivery, and manufacturing processes is subject to intense legal battles among key players. Disputes over core patents could restrict market access for developing companies, create licensing uncertainties, and increase legal costs across the industry. Court rulings that invalidate or narrow key patents may reduce incentives for continued innovation, while conversely, overly broad patent protection could stifle competition and maintain high prices. As the market matures, the resolution of these intellectual property conflicts will determine the competitive landscape, potentially delaying product launches and limiting the number of players capable of commercializing new mRNA therapies.

Covid-19 Impact:

The COVID-19 pandemic served as the definitive catalyst for mRNA therapeutics, compressing decades of potential development into just two years. Emergency use authorizations provided real-world safety data on millions of recipients, building regulatory frameworks for future approvals. Manufacturing capacity expanded exponentially, with new facilities constructed globally to meet vaccine demand, creating infrastructure now available for other mRNA products. Supply chain networks for raw materials including modified nucleotides and lipids matured substantially. The pandemic also fostered unprecedented collaboration between academic institutions, biotechnology companies, and government agencies, establishing partnerships that continue to advance the pipeline. Post-pandemic, the mRNA platform is positioned as a cornerstone of modern medicine rather than an experimental approach.

The Infectious Diseases segment is expected to be the largest during the forecast period

The Infectious Diseases segment is expected to account for the largest market share during the forecast period, building directly on the momentum established by COVID-19 vaccines. Beyond SARS-CoV-2, mRNA candidates targeting influenza, respiratory syncytial virus, human immunodeficiency virus, Zika virus, and cytomegalovirus are advancing through clinical development. Seasonal flu vaccines produced via mRNA offer potential advantages in manufacturing speed, allowing strain matching closer to flu season onset. Combination vaccines addressing multiple respiratory pathogens in a single injection are in development, simplifying immunization schedules. The established regulatory pathways for infectious disease vaccines, combined with government stockpiling programs and global health organization procurement, ensure this segment maintains dominance throughout the forecast timeline.

The Pharmaceutical & Biotechnology Companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Pharmaceutical & Biotechnology Companies segment is predicted to witness the highest growth rate, driven by aggressive pipeline expansion and manufacturing scale-up activities. Major pharmaceutical corporations are investing heavily in mRNA platforms, establishing in-house capabilities through both internal development and strategic acquisitions of specialized biotech firms. These companies are pursuing diverse applications beyond infectious diseases, including oncology, rare genetic disorders, and autoimmune conditions, leveraging mRNA's programmability. The segment benefits from substantial research and development budgets, existing commercial infrastructure, and regulatory expertise. As approved mRNA products transition from clinical trials to commercial launches, pharmaceutical and biotechnology companies capture increasing value, making this the fastest-growing end-user category.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, anchored by substantial government funding, a mature biotechnology ecosystem, and early adoption of COVID-19 vaccines. The United States invested billions through Operation Warp Speed and subsequent initiatives, creating domestic manufacturing capacity and supporting clinical research. Leading mRNA companies are headquartered in the region, maintaining intellectual property portfolios and production facilities. Regulatory agencies have established clear guidance pathways for mRNA products, reducing approval uncertainty. Strong healthcare infrastructure capable of meeting cold chain requirements further supports adoption. The combination of innovation leadership, manufacturing scale, and favorable reimbursement policies ensures North America's dominant market position throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by aggressive government investments in local manufacturing capacity and expanding clinical research infrastructure. China has prioritized mRNA technology development, with domestic companies advancing candidates for multiple indications and constructing large-scale production facilities. Japan, South Korea, and India are similarly investing in platform capabilities, recognizing mRNA's strategic importance for pandemic preparedness and chronic disease management. Large populations with high infectious disease burdens create substantial addressable markets for mRNA vaccines. Additionally, contract manufacturing organizations in the region are scaling operations to serve global pharmaceutical clients, accelerating technology transfer and workforce training, positioning Asia Pacific as the fastest-growing market for mRNA therapeutics.

Key players in the market

Some of the key players in MRNA Therapeutics Market include Moderna Inc., BioNTech SE, CureVac N.V., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, AstraZeneca plc, Arcturus Therapeutics Holdings Inc., Translate Bio Inc., eTheRNA immunotherapies NV, Gritstone bio Inc., Sangamo Therapeutics Inc., Argos Therapeutics Inc., Ethris GmbH, Panacea Biotec Limited and Takeda Pharmaceutical Company Limited.

Key Developments:

In April 2026, Moderna announced the initiation of a Phase 3 study for its investigational mRNA-based H5 pandemic influenza vaccine (mRNA-1018), with the first participants dosed in the U.S. and UK to address avian flu threats.

In March 2026, BioNTech outlined its "catalyst-rich" 2026 roadmap, aiming to have 15 Phase 3 clinical trials ongoing by year-end, specifically focusing on mRNA cancer immunotherapies and antibody-drug conjugates (ADCs).

In August 2025, Pfizer and BioNTech received FDA approval for their updated 2025-2026 formula COVID-19 vaccine, tailored to the KP.2 variant, maintaining their lead in the prophylactic mRNA vaccine segment.

Therapy Types Covered:

  • Prophylactic mRNA Therapeutics
  • Therapeutic mRNA Therapeutics

mRNA Construct Types Covered:

  • Conventional Non-replicating mRNA
  • Self-amplifying mRNA
  • Circular mRNA
  • Trans-amplifying mRNA

Delivery Systems Covered:

  • Lipid Nanoparticles
  • Polymer-based Systems
  • Cationic Nano-emulsions
  • Viral Vectors
  • Other Delivery Systems

Applications Covered:

  • Infectious Diseases
  • Oncology
  • Autoimmune Diseases
  • Rare & Genetic Disorders
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Contract Research Organizations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Procurement

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global mRNA Therapeutics Market, By Therapy Type

  • 5.1 Prophylactic mRNA Therapeutics
  • 5.2 Therapeutic mRNA Therapeutics

6 Global mRNA Therapeutics Market, By mRNA Construct Type

  • 6.1 Conventional Non-replicating mRNA
  • 6.2 Self-amplifying mRNA
  • 6.3 Circular mRNA
  • 6.4 Trans-amplifying mRNA

7 Global mRNA Therapeutics Market, By Delivery System

  • 7.1 Lipid Nanoparticles
  • 7.2 Polymer-based Systems
  • 7.3 Cationic Nano-emulsions
  • 7.4 Viral Vectors
  • 7.5 Other Delivery Systems

8 Global mRNA Therapeutics Market, By Application

  • 8.1 Infectious Diseases
  • 8.2 Oncology
  • 8.3 Autoimmune Diseases
  • 8.4 Rare & Genetic Disorders
  • 8.5 Other Applications

9 Global mRNA Therapeutics Market, By End User

  • 9.1 Hospitals & Clinics
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Research & Academic Institutes
  • 9.4 Contract Research Organizations

10 Global mRNA Therapeutics Market, By Distribution Channel

  • 10.1 Hospital Pharmacies
  • 10.2 Retail Pharmacies
  • 10.3 Online Pharmacies
  • 10.4 Direct Procurement

11 Global mRNA Therapeutics Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Moderna Inc.
  • 14.2 BioNTech SE
  • 14.3 CureVac N.V.
  • 14.4 Pfizer Inc.
  • 14.5 Sanofi SA
  • 14.6 GlaxoSmithKline plc
  • 14.7 AstraZeneca plc
  • 14.8 Arcturus Therapeutics Holdings Inc.
  • 14.9 Translate Bio Inc.
  • 14.10 eTheRNA immunotherapies NV
  • 14.11 Gritstone bio Inc.
  • 14.12 Sangamo Therapeutics Inc.
  • 14.13 Argos Therapeutics Inc.
  • 14.14 Ethris GmbH
  • 14.15 Panacea Biotec Limited
  • 14.16 Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1 Global mRNA Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global mRNA Therapeutics Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global mRNA Therapeutics Market Outlook, By Prophylactic mRNA Therapeutics (2023-2034) ($MN)
  • Table 4 Global mRNA Therapeutics Market Outlook, By Therapeutic mRNA Therapeutics (2023-2034) ($MN)
  • Table 5 Global mRNA Therapeutics Market Outlook, By mRNA Construct Type (2023-2034) ($MN)
  • Table 6 Global mRNA Therapeutics Market Outlook, By Conventional Non-replicating mRNA (2023-2034) ($MN)
  • Table 7 Global mRNA Therapeutics Market Outlook, By Self-amplifying mRNA (2023-2034) ($MN)
  • Table 8 Global mRNA Therapeutics Market Outlook, By Circular mRNA (2023-2034) ($MN)
  • Table 9 Global mRNA Therapeutics Market Outlook, By Trans-amplifying mRNA (2023-2034) ($MN)
  • Table 10 Global mRNA Therapeutics Market Outlook, By Delivery System (2023-2034) ($MN)
  • Table 11 Global mRNA Therapeutics Market Outlook, By Lipid Nanoparticles (2023-2034) ($MN)
  • Table 12 Global mRNA Therapeutics Market Outlook, By Polymer-based Systems (2023-2034) ($MN)
  • Table 13 Global mRNA Therapeutics Market Outlook, By Cationic Nano-emulsions (2023-2034) ($MN)
  • Table 14 Global mRNA Therapeutics Market Outlook, By Viral Vectors (2023-2034) ($MN)
  • Table 15 Global mRNA Therapeutics Market Outlook, By Other Delivery Systems (2023-2034) ($MN)
  • Table 16 Global mRNA Therapeutics Market Outlook, By Application (2023-2034) ($MN)
  • Table 17 Global mRNA Therapeutics Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 18 Global mRNA Therapeutics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 19 Global mRNA Therapeutics Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
  • Table 20 Global mRNA Therapeutics Market Outlook, By Rare & Genetic Disorders (2023-2034) ($MN)
  • Table 21 Global mRNA Therapeutics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 22 Global mRNA Therapeutics Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global mRNA Therapeutics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 24 Global mRNA Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 25 Global mRNA Therapeutics Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 26 Global mRNA Therapeutics Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 27 Global mRNA Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 28 Global mRNA Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 29 Global mRNA Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 30 Global mRNA Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 31 Global mRNA Therapeutics Market Outlook, By Direct Procurement (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.